Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Point Biopharma Global Inc (NQ: PNT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Point Biopharma Global Inc

< Previous 1 2 3 4 Next >
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole... 
Via Benzinga
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c 
Via Benzinga
Why is Prostate Cancer Focused Lantheus Stock Trading Lower Today?
Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic castration-res 
Via Benzinga
Top 5 Health Care Stocks That May Collapse In November
As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Recap: POINT Biopharma Global Q3 Earnings
Via Benzinga
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Stock Market Ends On High Note Even As Yields Soar; Tesla In Focus: Weekly Review
A rally attempt continues amid soaring Treasury yields. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Why Point BioPharma Global Stock Skyrocketed 86% This Week
Point Biopharma is being acquired by Eli Lilly. Here's what investors need to know. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2023
Via Benzinga
Why Eli Lilly Stock Was Looking Sickly Today
Investors weren't necessarily satisfied with their company's latest asset buy. 
Via The Motley Fool
Crude Oil Moves Higher; POINT Biopharma Global Shares Jump
U.S. stocks extended losses toward the end of trading, with the S&P 500 falling around 1.5% on Tuesday. The Dow traded down 1.43% to 32,954.84 while the NASDAQ fell 1.98% to 13,044.24. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Shares of Point Biopharma Global Are Soaring Tuesday
The company entered into a buyout agreement with Eli Lilly. 
Via The Motley Fool
Why Getty Images Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Vericity, Inc. (NASDAQ: VERY) shares climbed 87.4% to $11.12 after iA Financial Group announced it will acquire the company. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Down Over 200 Points; US Job Openings Rise In August
U.S. stocks extended losses midway through trading, with the Nasdaq Composite falling more than 200 points on Tuesday. The Dow traded down 1.06% to 33,078.27 while the NASDAQ fell 1.60% to 13,094.83.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Point Biopharma Stock Nearly Doubles On Eli Lilly Deal
Eli Lilly is spending $1.4 billion on buying Point Biopharma Global Inc. Point Biopharma is a radiopharmaceutical company focused on cancer treatment. 
Via Talk Markets
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga
Vericity, POINT Biopharma Global, Oddity Tech And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite falling more than 100 points on Tuesday. Here are some big stocks recording gains in today’s session. Vericity, Inc. (NASDAQ: VERY) shares climbed... 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Falls Over 100 Points; McCormick Sales Miss Views
U.S. stocks traded lower this morning, with the Dow Jones falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.37% to 33,310.99 while the NASDAQ fell... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Point Biopharma Stock Launches 84% On Eli Lilly's $1.4 Billion Takeover
The company is working on targeted radiation therapy with prostate cancer results up next. 
Via Investor's Business Daily
HPQ Stock Alert: HP Just Scored a Double Upgrade From Bank of America
HP is in the news Tuesday after shares of HPQ stock got a double upgrade and price target increase from Bank of America this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Cancer Treatment Focused POINT Biopharma Stock Trading Higher Today?
Eli Lilly And Co (NYSE: LLY) agreed to acquire POINT Biopharma Global Inc (NASDAQ: PNT) at $12.50 per share in cash, an aggregate of  
Via Benzinga
Why Is Point Biopharma (PNT) Stock Up 84% Today?
Point Biopharma stock is heading higher on Tuesday as investors react to news of Eli Lilly acquiring the shares of PNT for $12.50 each. 
Via InvestorPlace
A Look Into Healthcare Sector Value Stocks
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. 
Via Investor's Business Daily
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.